Properties of a recombinant yeast-derived hepatitis B surface antigen containing S, preS2 and preS1 antigenic domains.
Yeast cells have been engineered to express mixed HBsAg particles containing the S and a modified large (L*) protein. Their construction resulted in reduced protease sensitivity, reduced glycosylation and complete inactivation of the polymerized human albumin binding site. The particles exposed the S, preS1 and preS2 antigenic determinants and induced an immune response against the three domains. Highly purified preparations have been obtained and are presently being tested in human volunteers.
D000818:Animals; D000917:Antibody Formation / Q000276:immunology*; D010450:Endopeptidases / Q000494:pharmacology; D000939:Epitopes; D006023:Glycoproteins / Q000096:biosynthesis; D006031:Glycosylation; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis* / Q000187:drug effects / Q000235:genetics* / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D006801:Humans; D051379:Mice; D011498:Protein Precursors / Q000235:genetics*; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics; D015003:Yeasts / Q000235:genetics
D000939:Epitopes; D006023:Glycoproteins; D006514:Hepatitis B Surface Antigens; D011498:Protein Precursors; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; C050806:presurface protein 1, hepatitis B surface antigen; C050807:presurface protein 2, hepatitis B surface antigen; D010450:Endopeptidases